Clinical trials: Epithelial Tumor, Malignant
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Prostate Carcinoma
A Prospective, Single-centre，Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis
Prostate carcinoma (PC) is common malignancy and is considered to be the highest incidence in the old males. The traditional diagnostic methods of PC present with some shortcomings.
- Trial name
- NCT04699344
- Testing
- The level of CNV
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Unresectable Hepatocellular Carcinoma
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
- Trial name
- NCT06593964
- Testing
- Thermosensitive Nanogel Embolic Agent
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Cirrhosis of Liver
Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Current practice guidelines recommend surveillance for hepatocellular carcinoma (HCC) in liver cirrhosis patients with ultrasonography (USG) every 6 months.
- Trial name
- PRIUS (NCT01446666)
- Where
- South Korea
- Volunteers
- 423 people
- Sponsor
- Asan Medical Center
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Cholangiocarcinoma
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma.
- Trial name
- NCT01673802
- Testing
- CT scan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Hepatocellular Carcinoma(HCC)
Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)
Till now, trans-arterial chemoembolization (TACE) is still one of the common modalities in treating hepatocellular carcinoma patients with unresectable intermediate stage.
- Trial name
- TASABR (NCT02921139)
- Testing
- Stereotactic ablative radiotherapy (SABR), Re-Transcatheter arterial chemoembolization (re-TACE)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Dalin Tzu Chi General Hospital
Nasopharyngeal Cancinoma (NPC)
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart, followed by treatment allocation…
- Trial name
- RAPID (NCT07904819)
- Testing
- Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM)
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Stage IV NSCLC
Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer
This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.
- Trial name
- NCT01640730
- Testing
- Kanglaite Injection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- KangLaiTe USA
UTUC, NAC
Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma
Upper urinary tract urothelial carcinoma (UTUC) represents a rare yet aggressive malignancy associated with a dismal prognosis. At the point of diagnosis, nearly half of the patients already have invasive disease, and over 70%…
- Trial name
- NCT06927128
- Testing
- Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Changhai Hospital
Ovarian Cancer
Fermented Wheat Germ Extract in Women With Ovarian Cancer
The main purpose of this Pilot Study is to test the safety, tolerability and quality of life in women who take Fermented Wheat Germ Extract (FWGE), to determine if an active form of FWGE can be detected in the blood, and…
- Trial name
- NCT02411565
- Testing
- Fermented Wheat Germ Extract (FWGE), Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is still very low. Bortezomib is currently approved to treat myeloma in patients who have already been treated.
- Trial name
- NCT00516100
- Testing
- bortezomib
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aptium Oncology Research Network
Cervical Cancer, Endometrial Cancer
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause…
- Conditions
- Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications
- Trial name
- NCT01672892
- Testing
- Standard radiation therapy, intensity-modulated radiation therapy
- Where
- 137 sites in United States, Canada and 2 more
- Volunteers
- 289 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Non Small Cell Lung Cancer
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
In France, lung cancer is responsible for more than 30000 each year. Progress was made in treatment of lung cancer in the last five years due to targeted therapies and to strategical evolutions consisting in a best adjustment of…
- Trial name
- NCT01631136
- Testing
- Cisplatin, Pemetrexed, Gemcitabine
- Where
- 91 sites in France
- Volunteers
- 932 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Carcinoma, Basal Cell
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic…
- Trial name
- NCT03897036
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Senhwa Biosciences, Inc.
Carcinoma, Pancreatic
Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer
This study aims to explore the efficacy and safety of intra- arterial infusion of gemcitabine and oxaliplatin in locally advanced pancreatic cancer.
- Trial name
- NCT02635971
- Testing
- Transcatheter arterial infusion, Intravenous chemotherapy, Gemcitabine
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Carcinoma, Non-small Cell Lung
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.
- Trial name
- NCT01514864
- Testing
- Dasatinib
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma
A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma
This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour.
- Trial name
- NCT01223209
- Testing
- LTX-315
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Lytix Biopharma AS
Non-small Cell Lung Cancer
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed.
- Trial name
- UV1-hTERT2012L (NCT01789099)
- Testing
- UV1 synthetic peptide vaccine and GM-CSF
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Ultimovacs ASA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.